Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;42(3):407-17.
doi: 10.1016/j.rdc.2016.03.001. Epub 2016 Jun 21.

Use of Biologics in Sjögren's Syndrome

Gaetane Nocturne  1 , Divi Cornec  2 , Raphaèle Seror  1 , Xavier Mariette  3
Affiliations
Review

Use of Biologics in Sjögren's Syndrome

Gaetane Nocturne et al. Rheum Dis Clin North Am. 2016 Aug.

Abstract

The management of patients suffering from primary Sjögren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking. However, progress made in the understanding of pSS pathogenesis has allowed moving into a more targeted approach to therapeutic intervention. Given the key role of chronic B-cell activation, B-cell target therapies were the first candidates. New pathways are currently being investigated, including costimulation and ectopic germinal center. In this review, we summarize the current evidence regarding B-cell targeted and anti-TNF therapies and provide an overview of promising drugs in the pipeline.

Keywords: Biological treatment; B cell; Clinical trials; Outcome measure; Primary Sjögren’s syndrome.

PubMed Disclaimer

Similar articles

  • Emerging drugs for primary Sjögren's syndrome.
    Gandolfo S, De Vita S. Gandolfo S, et al. Expert Opin Emerg Drugs. 2019 Jun;24(2):121-132. doi: 10.1080/14728214.2019.1634052. Expert Opin Emerg Drugs. 2019. PMID: 31286787 Review.
  • SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
    Andréu Sánchez JL, Fernández Castro M, Del Campo Fontecha PD, Corominas H, Narváez García FJ, Gómez de Salazar JR, Rua-Figueroa Í, Abad Hernández MÁ, Álvarez Rivas MN, Montes JDP, Francisco Hernández FM, Gantes Pedraza MÁ, Greco Merino MG, Hernández MV, Navarro Compán MV, Solarte JAP, Romero Bueno FI, Park HS, Sivera Mascaró F. Andréu Sánchez JL, et al. Reumatol Clin (Engl Ed). 2019 Nov-Dec;15(6):315-326. doi: 10.1016/j.reuma.2018.10.014. Epub 2019 Jan 23. Reumatol Clin (Engl Ed). 2019. PMID: 30683506 English, Spanish.
  • New biological therapies in Sjögren's syndrome.
    Nocturne G, Cornec D, Seror R, Mariette X. Nocturne G, et al. Best Pract Res Clin Rheumatol. 2015 Dec;29(6):783-93. doi: 10.1016/j.berh.2016.02.009. Epub 2016 Mar 24. Best Pract Res Clin Rheumatol. 2015. PMID: 27107513 Review.
  • Primary Sjogren's syndrome: current and prospective therapies.
    Thanou-Stavraki A, James JA. Thanou-Stavraki A, et al. Semin Arthritis Rheum. 2008 Apr;37(5):273-92. doi: 10.1016/j.semarthrit.2007.06.002. Epub 2007 Aug 21. Semin Arthritis Rheum. 2008. PMID: 17714766 Review.
  • Biologics in Sjögren's syndrome.
    Skarlis C, Marketos N, Mavragani CP. Skarlis C, et al. Pharmacol Res. 2019 Sep;147:104389. doi: 10.1016/j.phrs.2019.104389. Epub 2019 Aug 12. Pharmacol Res. 2019. PMID: 31415917 Review.
See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources